Impact of IBS With Constipation and Chronic Constipation on Women's Health: Current Concepts and Considerations CME/CE

Author Information and Disclosures

Release Date: April 30, 2008; Valid for credit through April 30, 2009

Credits Available
Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.5 nursing contact hours (0.5 contact hours are in the area of pharmacology);
Pharmacists - 1.5 ACPE continuing education credits for pharmacists (0.15 CEUs)

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Sucampo, Takeda
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Review current concepts in the epidemiology and prevalence of IBS with constipation/chronic constipation, with a focus on women
  2. Recognize the current challenges in diagnosis facing the clinician treating patients/women with IBS with constipation/chronic constipation, acknowledging the role of abdominal pain in differentiating the 2 conditions
  3. Discuss the impact of IBS with constipation/chronic constipation within the context of its effect on women's health
  4. Describe current strategies in the management of IBS with constipation and chronic constipation, ranging from traditional to novel approaches
Authors and Disclosures

Lin Chang, MD
Disclosure: Lin Chang, MD, has disclosed that she has received grants for clinical research from GlaxoSmithKline and Prometheus. Dr. Chang has also disclosed that she has served as an advisor or consultant to GlaxoSmithKline, Prometheus, Takeda, Microbia, Forest, and Salix.


Trinh T. Truong, MD
Disclosure: Trinh T. Truong, MD, has disclosed no relevant financial relationships.


Maria L. Gaiso, PhD
Disclosure: Maria Gaiso has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

 
This Activity is sponsored by Medscape Continuing Education Provider Unit.

Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 1.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.5 contact hours are in the area of pharmacology.

Provider Number: 6FDKKC-PRV-05

Contact This Provider

 
ACPE logoMedscape is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Medscape is accredited by the American Council on Pharmacy Education as a provider of continuing pharmacy education. Medscape designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the American Council on Pharmacy Education (Universal Program Number 461-000-08-012-H01-P).

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.